Selwan Khamisi

Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Lindholm, Lars; Sjölin, Gabriel; Jonsson, Annika; Abraham‐Nordling, Mirna et al.

Ingår i Endocrinology, Diabetes & Metabolism, 2025

• DOI för Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Estimation of kidney function in Graves' disease using creatinine and cystatin C

Abbaszadeh, Sorena; Lundqvist, Martin H.; Ljunggren, Östen; Larsson, Anders Olof et al.

Ingår i Endocrine Connections, 2025

• DOI för Estimation of kidney function in Graves' disease using creatinine and cystatin C
• Ladda ner fulltext (pdf) av Estimation of kidney function in Graves' disease using creatinine and cystatin C

Fracture Incidence in Graves' Disease: A Population-Based Study

Khamisi, Selwan; Udumyan, Ruzan; Sjölin, Gabriel; Calissendorff, Jan et al.

Ingår i Thyroid, s. 1349-1357, 2023

• DOI för Fracture Incidence in Graves' Disease: A Population-Based Study

Long-Term Outcome of Graves' Disease: A Gender Perspective

Calissendorff, Jan; Cramon, Per Karkov; Hallengren, Bengt; Khamisi, Selwan et al.

Ingår i Women's Health Reports, s. 487-496, 2023

• DOI för Long-Term Outcome of Graves' Disease: A Gender Perspective
• Ladda ner fulltext (pdf) av Long-Term Outcome of Graves' Disease: A Gender Perspective

Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Khamisi, Selwan; Karlsson, Anders; Ljunggren, Östen; Thulin, Måns et al.

Ingår i Cytokine, s. 156269, 2023

• DOI för Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
• Ladda ner fulltext (pdf) av Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Lindholm, Lars; Sjölin, Gabriel; Jonsson, Annika; Abraham‐Nordling, Mirna et al.

Ingår i Endocrinology, Diabetes & Metabolism, 2025

• DOI för Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Estimation of kidney function in Graves' disease using creatinine and cystatin C

Abbaszadeh, Sorena; Lundqvist, Martin H.; Ljunggren, Östen; Larsson, Anders Olof et al.

Ingår i Endocrine Connections, 2025

• DOI för Estimation of kidney function in Graves' disease using creatinine and cystatin C
• Ladda ner fulltext (pdf) av Estimation of kidney function in Graves' disease using creatinine and cystatin C

Fracture Incidence in Graves' Disease: A Population-Based Study

Khamisi, Selwan; Udumyan, Ruzan; Sjölin, Gabriel; Calissendorff, Jan et al.

Ingår i Thyroid, s. 1349-1357, 2023

• DOI för Fracture Incidence in Graves' Disease: A Population-Based Study

Long-Term Outcome of Graves' Disease: A Gender Perspective

Calissendorff, Jan; Cramon, Per Karkov; Hallengren, Bengt; Khamisi, Selwan et al.

Ingår i Women's Health Reports, s. 487-496, 2023

• DOI för Long-Term Outcome of Graves' Disease: A Gender Perspective
• Ladda ner fulltext (pdf) av Long-Term Outcome of Graves' Disease: A Gender Perspective

Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Khamisi, Selwan; Karlsson, Anders; Ljunggren, Östen; Thulin, Måns et al.

Ingår i Cytokine, s. 156269, 2023

• DOI för Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
• Ladda ner fulltext (pdf) av Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy

Khamisi, Selwan; Lundqvist, Martin; Edén Engström, Britt; Larsson, Anders et al.

Ingår i Experimental and clinical endocrinology & diabetes, s. 236-241, 2023

• DOI för Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy
• Ladda ner fulltext (pdf) av Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy

Vitamin D and bone metabolism in Graves’ disease: a prospective study

Khamisi, Selwan; Lundqvist, Martin H.; Rasmusson, Annica J.; Edén Engström, Britt et al.

Ingår i Journal of Endocrinological Investigation, s. 425-433, 2023

• DOI för Vitamin D and bone metabolism in Graves’ disease: a prospective study
• Ladda ner fulltext (pdf) av Vitamin D and bone metabolism in Graves’ disease: a prospective study

Long term outcome after toxic nodular goitre

Sjolin, Gabriel; Watt, Torquil; Bystrom, Kristina; Calissendorff, Jan et al.

Ingår i Thyroid Research, 2022

• DOI för Long term outcome after toxic nodular goitre
• Ladda ner fulltext (pdf) av Long term outcome after toxic nodular goitre

Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'

Sjölin, Gabriel; Byström, Kristina; Holmberg, Mats; Törring, Ove et al.

Ingår i Endocrinology, Diabetes & Metabolism, 2021

• DOI för Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'
• Ladda ner fulltext (pdf) av Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'

Serum thyroglobulin is associated with orbitopathy in Graves' disease

Khamisi, Selwan; Lundqvist, Martin H.; Emadi, P.; Almby, Kristina E. et al.

Ingår i Journal of Endocrinological Investigation, s. 1905-1911, 2021

• DOI för Serum thyroglobulin is associated with orbitopathy in Graves' disease
• Ladda ner fulltext (pdf) av Serum thyroglobulin is associated with orbitopathy in Graves' disease

Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey

Törring, Ove; Watt, Torquil; Sjölin, Gabriel; Byström, Kristina et al.

Ingår i Thyroid, s. 322-331, 2019

• DOI för Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey

The Long-Term Outcome of Treatment for Graves' Hyperthyroidism

Sjölin, Gabriel; Holmberg, Mats; Törring, Ove; Byström, Kristina et al.

Ingår i Thyroid, s. 1545-1557, 2019

• DOI för The Long-Term Outcome of Treatment for Graves' Hyperthyroidism

A rare case of dyshormonogenetic fetal goiter responding to intra-amniotic thyroxine injections

Khamisi, Selwan; Lindgren, Peter; Karlsson, F Anders

Ingår i European thyroid journal, s. 51-56, 2014

• DOI för A rare case of dyshormonogenetic fetal goiter responding to intra-amniotic thyroxine injections

Graves' Disease; Aspects on Orbitopathy and Bone Metabolism

Khamisi, Selwan

2023

• Ladda ner fulltext (pdf) av Graves' Disease; Aspects on Orbitopathy and Bone Metabolism